Resistance Oncology ApS: Financial statements 2024
CVR: 36945125
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -15,712 and a net result of DKK -29,048 compared with DKK -22,028 the year before. Equity in the 2024 report amounted to DKK 307,493. The solvency ratio was 68.7%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -15,712
- Profit/Loss
- DKK -29,048
- Equity
- DKK 307,493
- Total Assets
- DKK 447,624
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -16K | -29K | 307K | 2 |
| 2023 | - | -21K | -22K | -63K | 1 |
| 2022 | - | -12K | -10K | -41K | - |
| 2021 | - | -10K | -9K | -31K | - |
| 2020 | - | -10K | -8K | -23K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
On November 18, 2024, the company changed its name from 3B-Oncology ApS to Resistance Oncology ApS.
Resistance Oncology ApS has published its annual report for 2023. Gross profit came to DKK -21,005, and the net result was DKK -22,028.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Kasper Pasternak Jørgensen and Nils Aage Brünner. The company is owned by TIMPCO-RO ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees (2016). In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity in the 2025 report amounted to DKK 325,631.